MAXON
19.1.2021 16:52:50 CET | Business Wire | Press release
Today, Maxon announced it has completed the transaction to acquire the business segment of its Japanese distributor that services Maxon’s community and business concerns, and the formation of the first official office in Japan: Maxon Computer KK. For the last ten years, Maxon’s Japan Representative office in Tokyo, TMS Corp , has been well-known amongst the Maxon community. The establishment of Maxon Computer KK seeks to deepen this connection and show Maxon’s ongoing commitment to the Japanese market. Maxon have also announced that TMS Corp founder, Manfred Flick, has been appointed as the Regional Director of this new subsidiary. In addition, his entire motivated team will be part of the Maxon family.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005758/en/
TMS Corp specializes in the broadcast, industrial design, architectural design, event and exhibition, and game development industries in this region, within which Cinema 4D already has a strong established presence. Many major TV stations in Japan already rely on Cinema 4D in production, as do many design departments for notable industrial companies and this acquisition will therefore be welcome news for these companies.
“Japan has been and continues to be a huge growth area for Maxon,” says Maxon CEO, David McGavran. “The TMS team have been strong partners in the region. Their expertise will be invaluable in our efforts to grow the influence of our Redshift, Red Giant and Cinema 4D product lines in Japan and APAC.”
Benefits for Users
Through this acquisition Maxon aims to strengthen their support system and outreach for the large number of product users in the country, who will benefit from Maxon’s ongoing provision of regular free seminars. Moreover, the inclusion of Red Giant and Redshift products, as well as the full Maxon One bundle, will certainly provide many more exciting tools for creatives to explore.
About Manfred Flick, Regional Director of Maxon KK
In 1994, Manfred founded TMS Corp. in Tokyo after having worked eight years in Japan as a broadcast engineer for a German company. A visit to the Siggraph trade show in 1998 in Los Angeles led him to the Maxon booth where he witnessed the popularity and potential of Cinema 4D for the first time. This kicked off an invaluable more than two-decade long relationship which has opened the door to Japan for Maxon. For TMS it was an exciting challenge to introduce a new product into a competitive market. Through tenacity, patience and enthusiasm Manfred and his experienced team, Cinema 4D has quickly become an essential tool in all design industries, and Maxon’s Red Giant and Redshift product lines are quickly gaining that same popularity.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Its product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology, the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools, and the high-end production, blazingly fast Redshift rendering solutions.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From its popular, inclusive events to its free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to Maxon’s ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005758/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom